Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2021 Apr 28;59(5):530–533. doi: 10.1007/s12275-021-1095-7

Differences in seroprevalence between epicenter and non-epicenter areas of the COVID-19 outbreak in South Korea

Hye Won Jeong 1,2,#, Hyun-Ha Chang 3,#, Eun Ji Kim 4,#, Yu Kyung Kim 5, Se-Mi Kim 4, Eun-Ha Kim 4, Young-Il Kim 4, Mark Anthony B Casel 4, Seong-Gyu Kim 4, Rare Rollon 4, Seung-Gyu Jang 4, Kwang-Min Yu 4, Hee-Sung Kim 2, Hee Sue Park 6, Su-Jin Park 7, Yong-Dae Kim 8,9, Eung-Gook Kim 4, Young Ki Choi 4,✉
PMCID: PMC8079228  PMID: 33907974

Abstract

To compare the standardized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence of high epicenter region with non-epicenter region, serological studies were performed with a total of 3,268 sera from Daegu City and 3,981 sera from Chungbuk Province. Indirect immunofluorescence assay (IFA) for SARS-CoV-2 IgG results showed a high seroprevalence rate in the Daegu City (epicenter) compared with a non-epicenter area (Chungbuk Province) (1.27% vs. 0.91%, P = 0.0358). It is noteworthy that the highest seroprevalence in Daegu City was found in elderly patients (70’s) whereas young adult patients (20’s) in Chungbuk Province showed the highest seroprevalence. Neutralizing antibody (NAb) titers were found in three samples from Daegu City (3/3, 268, 0.09%) while none of the samples from Chungbuk Province were NAb positive. These results demonstrated that even following the large outbreak, the seropositive rate of SARS-CoV-2 in the general population remained low in South Korea.

Keywords: SARS-CoV-2, COVID-19, epicenter, seroprevalence, South Korea

Acknowledgments

This work was supported by Research Center for Severe Pulmonary Disease (2020R1A5A2017476) from The National Research Foundation.

Conflict of Interest

We have no conflict of interest to report.

Footnotes

These authors contributed equally to this work.

References

  1. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, Taylor J, Spicer K, Bardossy AC, Oakley LP, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N. Engl. J. Med. 2020;382:2081–2090. doi: 10.1056/NEJMoa2008457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. COVID-19 National Emergency Response Center. Epidemiology and Case Management Team. Korea Centers for Disease Control and Prevention Early epidemiological and clinical characteristics of 28 cases of coronavirus disease in South Korea. Osong Public Health Res. Perspect. 2020;11:8–14. doi: 10.24171/j.phrp.2020.11.1.03. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eckerle I, Meyer B. SARS-CoV-2 seroprevalence in COVID-19 hotspots. Lancet. 2020;396:514–515. doi: 10.1016/S0140-6736(20)31482-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Guan W, Ni J, Hu Y, Liang C, Ou C, He J, Liu L, Shan H, Lei C, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. He J, Guo Y, Mao R, Zhang J. Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis. J. Med. Virol. 2021;93:820–830. doi: 10.1002/jmv.26326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jeong HW, Kim SM, Kim HS, Kim YI, Kim JH, Cho JY, Kim S, Kang H, Kim SG, Park SJ, et al. Viable SARS-CoV-2 in various specimens from COVID-19 patients. Clin. Microbiol. Infect. 2020;26:1520–1524. doi: 10.1016/j.cmi.2020.07.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ko JH, Joo EJ, Park SJ, Baek JY, Kim WD, Jee J, Kim CJ, Jeong C, Kim YJ, Shon HJ, et al. Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients. J. Clin. Med. 2020;9:2268. doi: 10.3390/jcm9072268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Korea Disease Control and Prevention Agency (KDCA) Updates on COVID-19 in Republic of Korea. 2020. [Google Scholar]
  10. Korean Society of Infectious Diseases. Korean Society of Pediatric Infectious Diseases. Korean Society of Epidemiology. Korean Society for Antimicrobial Therapy. Korean Society for Healthcare-associated Infection Control and Prevention. Korea Centers for Disease Control and Prevention Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J. Korean Med. Sci. 2020;16:e112. doi: 10.3346/jkms.2020.35.e112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, Wang L, Zhang L, Li QH, Zhao L, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur. Respir. J. 2020;55:2001112. doi: 10.1183/13993003.01112-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on 165 board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25:2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Noh JY, Seo YB, Yoon JG, Seong H, Hyun H, Lee J, Lee N, Jung S, Park MJ, Song W, et al. Seroprevalence of anti-SARS-CoV-2 antibodies among outpatients in southwestern Seoul, Korea. J. Korean Med. Sci. 2020;35:e311. doi: 10.3346/jkms.2020.35.e311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Park SJ, Yu KM, Kim YI, Kim SM, Kim EH, Kim SG, Kim EJ, Casel MAB, Rollon R, Jang SG, et al. Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets. mBio. 2020;11:e01114–20. doi: 10.1128/mBio.01114-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Peck KR. Early diagnosis and rapid isolation: response to COVID-19 outbreak in Korea. Clin. Microbiol. Infect. 2020;26:805–807. doi: 10.1016/j.cmi.2020.04.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ramachandran R. COVID-19-a very visible pandemic. Lancet. 2020;396:e13–e14. doi: 10.1016/S0140-6736(20)31673-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki SI, Ishihara T, Iwata M, Morise Z, Doi Y. Natural history of asymptomatic SARS-CoV-2 infection. N. Engl. J. Med. 2020;383:885–886. doi: 10.1056/NEJMc2013020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Song SK, Lee DH, Nam JH, Kim KT, Do JS, Kang DW, Kim SG, Cho MR. IgG Seroprevalence of COVID-19 among individuals without a history of the coronavirus disease infection in Daegu, Korea. J. Korean Med. Sci. 2020;35:e269. doi: 10.3346/jkms.2020.35.e269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Trinité B, Tarrés-Frexas F, Rodon J, Pradenas E, Urrea V, Marfil S, de la Concepción MLR, Ávila-Nieto C, Aguilar-Gurrieri C, Barajas A, et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Sci. Rep. 2021;11:2608. doi: 10.1038/s41598-021-81862-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Microbiology (Seoul, Korea) are provided here courtesy of Nature Publishing Group

RESOURCES